Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday. Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald cut Oramed Pharmaceuticals from an “overweight” rating to […]
Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $7.47 and traded as high as $8.29. Oramed Pharmaceuticals shares last traded at $7.96, with a volume of 188,755 shares traded. Analysts Set New Price Targets ORMP […]